PASADENA, Calif.--(BUSINESS WIRE)--Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergies and autoimmune disorders, today announced the completion of an oversubscribed $16 million Series A financing led by BOLD Capital Partners. Horizons Ventures, Tarrasque, Endurance28, Freeflow Ventures, and a syndicate of leading angel investors also participated in the round..

加利福尼亚州帕萨迪纳（商业新闻短讯）--Holocala是一家生物技术公司，率先开发针对过敏和自身免疫性疾病的蠕虫衍生疗法，今天宣布完成由BOLD Capital Partners牵头的1600万美元超额认购的a系列融资。Horizons Ventures、Tarrasque、Endurance28、Freeflow Ventures和一个由领先的天使投资者组成的财团也参加了这轮投资。

In connection with the financing, Peter Barton Hutt, former Chief Counsel for the Food and Drug Administration (FDA) and currently senior counsel at Covington & Burling LLP, has been appointed to the company’s Board of Directors.

在融资方面，前食品和药物管理局（FDA）首席顾问、现任Covington＆Burling LLP高级顾问彼得·巴顿·赫特（PeterBarton Hutt）已被任命为公司董事会成员。

The capital will be used to progress development of Holoclara’s orally available therapeutics into the clinic this year. The company additionally continues to advance its broader discovery engine to isolate and identify from worms particular molecules with therapeutic potential.

今年，该资金将用于推动霍洛克拉拉口服治疗药物的开发。该公司还继续推进其更广泛的发现引擎，以从蠕虫中分离和鉴定具有治疗潜力的特定分子。

“Holoclara was born out of an unmet clinical need. During my physician training, I met countless patients with life-altering allergies and autoimmune disorders that were often undiagnosed and untreated. Medicine lacked the tools to address these debilitating diseases — despite compelling evidence I and other worm scientists unearthed pointing to worms as a promising, if unexpected, therapeutic approach,” said Andrea Choe, M.D., Ph.D., co-founder and Chief Executive Officer of Holoclara.

Holocala的联合创始人兼首席执行官Andrea Choe博士说：“Holocala出生于一个未得到满足的临床需求。在我的医生培训期间，我遇到了无数患有改变生命的过敏和自身免疫性疾病的患者，这些患者往往未经诊断和治疗。医学缺乏解决这些使人衰弱的疾病的工具-尽管我和其他蠕虫科学家发现了令人信服的证据，指出蠕虫是一种很有前途的（如果出乎意料的话）治疗方法。”

“With our world-class team and leading investors, we are taking matters into our own hands to usher in a new era of medicines inspired by nature that can transform the lives of millions of people.”.

“凭借我们世界一流的团队和领先的投资者，我们正在自己动手，开创一个受大自然启发的药物新时代，可以改变数百万人的生活。”

The company’s discovery engine builds on Dr. Choe’s research uncovering a unique pheromone language shared by roundworms, which may have evolved over hundreds of millions of years. She further discovered molecules derived from these worms that blocked formation of disease in animal models of allergic and autoimmune disease.

该公司的发现引擎建立在Choe博士的研究基础上，该研究揭示了蛔虫共享的独特信息素语言，这种语言可能已经进化了数亿年。她进一步发现了来自这些蠕虫的分子，这些分子在过敏性和自身免疫性疾病的动物模型中阻止了疾病的形成。

These findings, published in the Proceedings of the National Academy of Sciences (PNAS) journal, became the foundation of Holoclara’s technology, enabling the company to replicate therapeutic molecules using synthetic chemistry for the development of safe and orally available medicines with the potential to treat, and even cure, prevalent diseases..

这些发现发表在《美国国家科学院院刊》（PNAS）上，成为Holoclara技术的基础，使该公司能够使用合成化学复制治疗分子，以开发安全且口服的药物，从而有可能治疗甚至治愈流行疾病。

'Holoclara’s ‘against the grain’ approach of seeking inspiration from worms intrigued the BOLD Capital team from the very start,” said Neal Bhadkamkar, Ph.D., General Partner of BOLD Capital Partners and member of Holoclara’s Board of Directors. “By focusing on a particular worm species that had co-evolved with humans over hundreds of thousands of years as a gut-resident parasite, Holoclara discovered powerful immune modulatory compounds in their secretions.

“霍洛克拉拉从蠕虫身上寻求灵感的‘反谷物’方法从一开始就引起了BOLD Capital团队的兴趣，”BOLD Capital Partners的普通合伙人兼霍洛克拉拉董事会成员尼尔·巴德卡姆卡（NealBhadkamkar）博士说。“通过关注一种特定的蠕虫物种，这种蠕虫作为肠道寄生虫与人类共同进化了数十万年，霍洛克拉拉在其分泌物中发现了强大的免疫调节化合物。

The company is mining this previously unexplored vein for the potential to create therapies for chronic inflammatory conditions that work with the immune system rather than against it.”.

该公司正在挖掘这种以前未被探索的静脉，以寻找治疗慢性炎症疾病的潜力，这种疾病与免疫系统有关，而不是对抗免疫系统。”

“I’m pleased to advise Holoclara as the company moves its groundbreaking science harnessing worm biology closer to the clinic and into the hands of countless patients suffering from allergic and autoimmune diseases today,” said Peter Barton Hutt. “Holoclara has assembled a strong and experienced scientific and medical team to pursue this new generation of medicine.”.

彼得·巴顿·赫特（PeterBarton Hutt）说：“我很高兴为霍洛克拉拉（Holocala）提供建议，因为该公司将其开创性的利用蠕虫生物学的科学更接近诊所，并将其交给了今天无数患有过敏性和自身免疫性疾病的患者。”。“霍洛克拉拉组建了一支强大而经验丰富的科学和医疗团队，致力于开发这一新一代医学。”。

Dr. Choe founded Holoclara with Paul W. Sternberg, Ph.D., professor at California Institute of Technology (Caltech), and Frank C. Schroeder, Ph.D., professor at Cornell University. Additional leading scientists and entrepreneurs sit on the company’s Board of Directors, including Dr. Bhadkamkar, Mr. Hutt, and Seemay Chou, Ph.D., CEO of Arcadia Science.

Choe博士与加州理工学院（Caltech）教授PaulW.Sternberg博士和康奈尔大学教授FrankC.Schroeder博士共同创立了Holocala。公司董事会中还有其他顶尖科学家和企业家，包括Bhadkamkar博士、Hutt先生和Arcadia Science首席执行官Seemay Chou博士。

Its advisors include Rick Maizels, Ph.D., professor at University of Glasgow; Brian Stoltz, Ph.D., professor at Caltech; Stan Lapidus, serial entrepreneur and former CEO of Cytyc Corporation and EXACT Sciences; Colleen Cutcliffe, Ph.D., CEO of Pendulum Therapeutics; Joe Betts-LaCroix, CEO of Retro Biosciences; and Carl LeBel, Ph.D., biotech executive formerly of Amgen, Otonomy, and Frequency Therapeutics..

其顾问包括格拉斯哥大学教授RickMaizels博士；加州理工学院教授布莱恩·斯托尔茨博士；斯坦·拉皮德斯（StanLapidus），连续创业者，Cytyc Corporation和EXACT Sciences前首席执行官；科琳·卡特克利夫博士，钟摆疗法首席执行官；Retro Biosciences首席执行官Joe Betts LaCroix；和Carl LeBel博士，生物技术执行官，前安进，耳科和频率治疗公司。

Holoclara is the first biotechnology company to create safe, orally available worm-derived therapies designed to provide relief to millions of people living with allergic and autoimmune disease. Founded and led by physician-scientist Andrea Choe, Holoclara mines potent immunomodulatory molecules from gut roundworms, building upon decades of preclinical data proving their therapeutic efficacy across a wide range of diseases.

Holocala是第一家创建安全、口服蠕虫衍生疗法的生物技术公司，旨在为数百万患有过敏性和自身免疫性疾病的人提供缓解。Holoclara由医学科学家Andrea Choe创立并领导，它从肠道蛔虫中挖掘出有效的免疫调节分子，建立在数十年的临床前数据基础上，证明了它们在多种疾病中的治疗效果。

With a team of world-renowned experts in worm biology and biotechnology and the backing of leading life sciences and technology investors, Holoclara is uniquely positioned to harness the therapeutic potential of worms to address historically untreatable diseases. To learn more, visit www.holoclara.com..

Holocala拥有一支世界知名的蠕虫生物学和生物技术专家团队，并得到了领先的生命科学和技术投资者的支持，它具有独特的优势，可以利用蠕虫的治疗潜力来解决历史上无法治愈的疾病。要了解更多信息，请访问www.holocala.com。